Clinical trials: Advanced Age
Fall Risk, Fall Risk, Fall Prevention
Prevention and Reduction of Falls: Testing and Evaluating Cutting Edge Haptic Technology
This study evaluates whether a drug-free, non-invasive haptic patch (LIBERTY Patch) affects fall-risk classification and balance/mobility confidence in adults ages 55 to 85.
- Conditions
- Fall Risk, Fall Risk, Fall Prevention, Accidental Falls, Accidental Falls/Prevention & Control
- Trial name
- PROTECT (NCT07781397)
- Testing
- LIBERTY Patch
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- SuperPatch Limited LLC
Type 2 Diabetes Mellitus (T2DM)
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Primary objective: Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: Treatment satisfaction
- Trial name
- ELDERLY-T (NCT05607160)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Sanofi
Depressive Disorder
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
The purpose of the study is to evaluate the long-term safety of saredutant (or SR48968C) in adult and elderly patients with depression.The primary objective is to evaluate the long-term safety and tolerability of a 100 mg dose of…
- Trial name
- NCT00250653
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- Sanofi
Influenza, Human
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects
Elderly healthy subjects will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
- Trial name
- NCT03657719
- Testing
- GC3114, GCFLU Quadrivalent
- Where
- South Korea
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Age-Related Muscle Weakness
Effect of Lactiplantibacillus Plantarum LM1001 on Muscle Strength in Older Adults
Purpose: This clinical trial aims to evaluate the efficacy and safety of Lactiplantibacillus plantarum LM1001 in improving muscle strength in older adults.
- Trial name
- NCT07538830
- Testing
- Lactiplantibacillus plantarum LM1001
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lactomason Co., Ltd.
Elderly, Pharmacokinetics
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms.
- Conditions
- Elderly, Pharmacokinetics, Overactive Bladder
- Trial name
- NCT00863551
- Testing
- Trospium Chloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allergan
Healthy
Study of an Extended Release (ER) Tablet, Single and Repeated Dosing
The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body).
- Trial name
- NCT00689039
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.
SB-742457 is a 5HT6 receptor antagonist that is in development for the symptomatic treatment of mild to moderate Alzheimer's disease . To date, all clinical trials have been conducted using a capsule formulation of SB-742457.
- Trial name
- NCT00551772
- Testing
- SB-742457
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Elderly, Parkinson Disease
A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
This study investigates the safety and tolerability of drug IkT-148009 in healthy elderly volunteers (55 to 70 years old). This first-in-human study is designed in 3 parts.
- Trial name
- NCT04350177
- Testing
- IkT-148009
- Where
- 4 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- ABLi Therapeutics, Inc.
Healthy Adult Subjects and Healthy Elderly Subjects
A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects
This is an investigator-and-subject blind, phase 1 study to characterize the safety, tolerability, pharmacokinetics and central and peripheral pharmacodynamics of 14-day repeated ascending doses of PF-06648671 once a day in…
- Trial name
- NCT02440100
- Testing
- PF-06648671, Midazolam
- Where
- Belgium
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults
This is a Phase I/II, randomised, multicentre, partially double-blind (group 1, 2, 4 and 5), parallel-group study designed to primarily evaluate the safety, tolerability and immune response in older adults (age 50 to 75 years)…
- Trial name
- NCT03437304
- Testing
- Immunose™ FLU 1%, Immunose™ FLU 2%, 200 μl, Immunose™ FLU 2%, 300 μl
- Where
- 5 sites in Sweden
- Volunteers
- 298 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Recovery of Function
Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)
Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET) A phase I, randomized, double-blind, placebo-controlled, single institutional pilot trial investigating the impact of nicotinamide…
- Trial name
- BestBet (NCT03635411)
- Testing
- Nicotinamide Riboside and Pterostilbene
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Elysium Health
Healthy Participants
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally administered BMS-986368 in healthy participants, healthy elderly participants, and healthy participants of japanese ethnicity.
- Trial name
- NCT06411730
- Testing
- BMS-986368
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy, Elderly
A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.
Evaluate the safety and tolerability of PF-04447943 after administration of multiple doses in healthy elderly participants. Evaluate plasma drug levels and effects on cognition.
- Trial name
- NCT00832052
- Testing
- PF-04447943
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.
- Trial name
- NCT04994717
- Testing
- Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
- Where
- 192 sites in United States, Australia and 30 more
- Volunteers
- 303 people
- Sponsor
- Amgen
Stroke Sequelae, Cognitive Impairment
Remote Bimanual Virtual Rehabilitation Post CVD
The aim of the study is to develop the BrightBrainer G (grasp), a game-based upper-extremity motor and cognitive rehabilitation system using custom virtual reality simulations.
- Conditions
- Stroke Sequelae, Cognitive Impairment, Depression
- Trial name
- NCT04713384
- Testing
- Integrative tele-rehalitation of chronic stroke survivors using custom therapeutic games
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Grigore Burdea
Influenza
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
- Trial name
- NCT00848848
- Testing
- Trivalent Influenza Vaccine, Trivalent Influenza Vaccine + high A, Trivalent Influenza Vaccine + ¼ dose adjuvant
- Where
- Belgium
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HI) at 21 days post…
- Trial name
- NCT00956449
- Testing
- Seasonal Influenza Vaccine
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes
This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes
- Trial name
- NCT00383578
- Testing
- Vildagliptin 100 mg qd, Metformin 1500 mg daily
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with…
- Trial name
- NCT00374296
- Testing
- MGCD0103
- Where
- 13 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.